CytoMed Therapeutics and SunAct Cancer Institute Launch Joint Cancer Research Project in India

The Singapore-based biotechnology company CytoMed Therapeutics has entered into a five-year research and business partnership with the SunAct Cancer Institute to conduct a Phase II study on cancer treatment in India. The study aims to evaluate the efficacy, safety, and tolerability of CytoMed's allogeneic gamma-delta T-cells in the therapy of various cancers, including solid tumors. This clinical project is financially supported by both partners and led by SunAct founder, oncologist and immunotherapy expert Dr. Vijay Patil. Dr. Patil emphasized the importance of collaborating with CytoMed to offer cost-effective alternatives for the treatment of solid tumors, which could benefit a large portion of the Indian population with cancer. Under the agreement, CytoMed provides scientific and technical support and undertakes the production of allogeneic gamma-delta T-cells. SunAct and Dr. Patil contribute their expertise in navigating Indian regulations as well as access to healthcare facilities and patient populations. Peter Choo, Chairman of CytoMed, stated that this cooperation supports the company's focus on developing new, affordable immunotherapies based on donor cells. At the same time, he looked forward to collaborating with Dr. Vijay Patil to advance the therapeutic application of CytoMed's patented allogeneic gamma-delta T-cells in India and beyond. Founded in 2018, CytoMed develops novel cell-based cancer immunotherapies using gamma-delta T-cell and gamma-delta natural killer cell technologies.